Teriflunomide Production Cost Reports

The report provides a detailed analysis essential for establishing a teriflunomide production plant. It encompasses all critical aspects necessary for teriflunomide production, including the cost of teriflunomide production, teriflunomide plant cost, teriflunomide production costs, and the overall teriflunomide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a teriflunomide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Teriflunomide is an oral immunomodulatory drug that is used to treat relapsing forms of multiple sclerosis (MS) in adults. It is clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. It works by preventing the enzyme dihydroorotate dehydrogenase (DHODH) in pyrimidine synthesis, which limits the proliferation of activated T and B lymphocytes that drive inflammation and myelin damage in MS. It provides convenient once-daily dosing with efficacy in decreasing MRI brain lesions.

It requires baseline liver function tests, strict pregnancy prevention due to teratogenic risks, and washout procedures upon discontinuation. Its common side effects include hair thinning, diarrhoea, elevated liver enzymes, and increased infection risk, which makes it unsuitable for immunocompromised patients or those needing live vaccines.

The market for teriflunomide is driven by the rising global burden of multiple sclerosis. Better diagnostics, greater awareness, and improved access to treatments in developing regions contribute to the market growth. Its ease of once-daily use compared to injections, better performance in cutting relapses and brain lesions, and safer profile versus stronger immunosuppressants fuel its market. The high branded costs, insurance coverage pushes, aid programs, and presence of generics affect industrial teriflunomide procurement. Other factors like hospital bids, local health budgets, steady supply, and competition from rival pills, plus needs for liver checks and birth control rules impacts its sourcing strategies.

Raw Material for Teriflunomide Production

According to the teriflunomide production plant project report, the key raw materials used in the production of teriflunomide include 5-methylisoxazole-4-carboxylic acid | 4-(trifluoromethyl)aniline |1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.

Production Process of Teriflunomide

The extensive teriflunomide production cost report consists of the following major industrial production process:

1. From direct amidation reaction: The synthesis of teriflunomide involves an EDC-promoted method. This method involves a direct amidation reaction where 5-methylisoxazole-4-carboxylic acid reacts with 4-(trifluoromethyl)aniline. The reaction is facilitated by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide as a promoter to give teriflunomide. The product is separated and purified to get pure teriflunomide as the final product.

Teriflunomide has the molecular formula of C12H9F3N2O2 with a molecular weight of 270.21 g/mol. It appears as a white to off-white crystalline powder with a melting point of 227-231 degree Celsius. It features a (Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide structure with moderate lipophilicity. It shows solubility in DMSO with a relative density of 1.424 g/cm³. Its stability requires storage at -20 degree Celsius powder or -80 degree Celsius solution. It is formulated with excipients like lactose monohydrate, hypromellose, and magnesium stearate. It shows high plasma protein binding (~99%) and oral bioavailability suited for once-daily MS dosing.